Koichi Sakurai
Overview
Explore the profile of Koichi Sakurai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
92
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Suda H, Eto S, Sakurai K
DEN Open
. 2024 Dec;
5(1):e70046.
PMID: 39712905
Vonoprazan is a novel acid blocker with greater potency than proton pump inhibitors. A Japanese study reported no significant safety concerns over 5 years of Vonoprazan use; however, elevated serum...
2.
Suda H, Sakurai K, Eto S, Fujie S, Okuda A, Takeichi T, et al.
Diagnostics (Basel)
. 2024 Nov;
14(22).
PMID: 39594206
: Proton pump inhibitor (PPI) use has increased worldwide, including in continuous and longer-term users. Recent reports highlight PPI-related endoscopic gastric mucosal changes, including fundic gland polyps, hyperplastic polyps, multiple...
3.
Nitta Y, Muraoka-Hirayama S, Sakurai K
Biochim Biophys Acta Mol Cell Biol Lipids
. 2020 Apr;
1865(8):158726.
PMID: 32335291
Although obesity contributes to the onset and pathogenesis of metabolic diseases, it has been repeatedly demonstrated that being overweight or mildly obese carries a survival advantage compared with being thin...
4.
Inamura A, Muraoka-Hirayama S, Sakurai K
Biol Pharm Bull
. 2019 Dec;
42(12):1977-1987.
PMID: 31787713
Gemcitabine (2,2-difluorodeoxycytidine nucleic acid), an anticancer drug exhibiting a potent ability to kill cancer cells, is a frontline chemotherapy drug. Although some chemotherapeutic medicines are known to induce nuclear DNA...
5.
Fujii S, Muraoka S, Miyamoto A, Sakurai K
Yakugaku Zasshi
. 2018 Jan;
138(1):73-81.
PMID: 29311467
Cytopenia is a major adverse event associated with linezolid therapy. The objective of this study was to examine whether the cytotoxicity of linezolid to eukaryotic cells was associated with mitochondrial...
6.
Muraoka S, Nitta Y, Yamada T, Sakuma Y, Ichimura A, Sakurai K
Yakugaku Zasshi
. 2017 Sep;
137(9):1137-1145.
PMID: 28867700
Cells have developed ingenious defense mechanisms in response to oxidative stress. Here, we evaluated changes in anti-oxidative capacity during differentiation of 3T3-L1 preadipocytes into adipocytes. When 3T3-L1 preadipocytes were treated...
7.
Tominaga K, Kato M, Takeda H, Shimoyama Y, Umegaki E, Iwakiri R, et al.
J Gastroenterol
. 2014 Feb;
49(10):1392-405.
PMID: 24535455
Background: The aim of this study was to investigate the efficacy of rikkunshito (RKT), a traditional Japanese medicine, combined with proton pump inhibitor (PPI) in patients with PPI-refractory non-erosive reflux...
8.
Fujii S, Takahashi S, Makino S, Kunimoto Y, Nakata H, Noda N, et al.
Chemotherapy
. 2014 Feb;
59(5):319-24.
PMID: 24480883
Background: Vancomycin and linezolid therapies are associated with renal dysfunction and thrombocytopenia, respectively. Methods: We retrospectively investigated Japanese patients with renal dysfunction or thrombocytopenia possibly associated with vancomycin and linezolid...
9.
Motoshige H, Oyama K, Takahashi K, Sakurai K
Biol Pharm Bull
. 2012 Nov;
35(11):1932-40.
PMID: 23123465
This study demonstrated gemcitabine-induced cytotoxicity in the insulinoma cell line INS-1. Gemcitabine inhibited INS-1 cell proliferation and maintained consistent cell number for 24 h, and then caused apoptosis within 48...
10.
Naoe H, Kaku E, Sakurai K, Sasaki Y
Nihon Shokakibyo Gakkai Zasshi
. 2012 Sep;
108(6):997, 1000-1.
PMID: 23016193
No abstract available.